Related Experiment Video
Updated: Jun 23, 2026
11:20
Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
Published on: March 29, 2018
Immunogenicity of bone morphogenetic proteins
Chang Ju Hwang1, Alexander R Vaccaro, James P Lawrence
1Department of Orthopaedic Surgery, Thomas Jefferson University and The Rothman Institute, Philadelphia, PA 19107, USA.
Journal of Neurosurgery. Spine
|May 16, 2009
Summary
Recombinant human bone morphogenetic proteins (rhBMPs) can trigger immune responses in some patients, but these responses do not lead to adverse clinical effects or safety issues. Further research is needed to fully understand BMP immunogenicity.
Area of Science:
- Biotechnology
- Immunology
- Orthopedics
Background:
- Bone morphogenetic proteins (BMPs) are crucial for bone formation and are used therapeutically.
- Recombinant human BMPs (rhBMPs) are engineered proteins used in regenerative medicine.
- Understanding the immunogenicity of rhBMPs is vital for patient safety.
Purpose of the Study:
- To review the immunogenicity of BMPs.
- To compare the immunogenicity and clinical outcomes of rhBMP-2 and rhOP-1 (BMP-7).
Main Methods:
- Literature review of therapeutic protein immunogenicity and clinical effects.
- Analysis of BMP characteristics related to immunogenicity.
- Comparison of antibody detection methods and results from clinical trials of rhBMP-2 and rhOP-1.
Main Results:
- rhBMPs, like other recombinant proteins, elicit immune responses in a subset of patients.
- No adverse clinical effects have been reported in patients with antibody formation to rhBMP-2 or rhOP-1.
- Antibody formation incidence was slightly higher in rhOP-1 trials compared to rhBMP-2 trials.
Conclusions:
- Immune responses to rhBMPs in patients do not correlate with clinical outcomes or safety parameters.
- Clinicians should remain aware of potential immunogenicity-related complications.
- Further studies are necessary to fully elucidate the safety profile of BMPs regarding immunogenicity.
